Could stem cell secretome beat standard care for knee arthritis?

NCT ID NCT07337863

Not yet recruiting Symptom relief Sponsor: Universitas Sriwijaya Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a substance made from stem cells (called secretome) can reduce pain and improve knee function in people with moderate knee osteoarthritis. Fifty adults aged 40-70 will receive either the secretome or a standard treatment (sodium hyaluronate) via injection into the knee. The goal is to see if the secretome works better for easing symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: umbilical cord-derived mesenchymal stem cell secretome
What this could lead to: If it works, this could offer a new way to ease knee pain and improve function in people with moderate knee osteoarthritis.
What could go wrong: This is an early-to-mid-stage trial with only 50 participants, so results may not apply to everyone. The secretome is experimental and its long-term safety and effectiveness are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS (KNEE OA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KNEE OSTEOARTHRITIS (KNEE OA)

Contacts and locations

Locations

RSUP Dr. Mohammad Hoesin Palembang

Palembang, South Sumatera, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.